Does Farxiga (dapagliflozin) cause rash?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Farxiga (Dapagliflozin) Cause Rash?

Yes, Farxiga can cause rash, but it occurs infrequently—affecting approximately 1.1% of patients—and is typically mild, rarely requiring drug discontinuation. 1, 2

Incidence and Characteristics

  • Rash occurs in 1.1% of dapagliflozin-treated patients, which is identical to the rate seen with placebo or active comparators (1.1%), indicating this is not a drug-specific effect 2

  • Serious hypersensitivity reactions are rare, occurring in only 0.2% of dapagliflozin patients versus 0.1% of comparators 2

  • Other skin-related adverse events include eczema (0.6%), dermatitis (0.5%), and urticaria (0.5%), all occurring at similar or lower rates compared to placebo 2

  • Drug discontinuation due to hypersensitivity reactions occurs in ≤0.2% of patients, demonstrating that most skin reactions are manageable 2

Timing and Presentation

  • Rash typically develops within days to weeks after starting dapagliflozin, consistent with drug-induced hypersensitivity reactions 3, 4

  • The FDA label specifically lists rash as a symptom of potential allergic reaction, along with hives and swelling of the face, lips, tongue, and throat 1

True Allergic Reactions vs. Common Rash

If you observe rash with any of the following features, this represents a serious allergic reaction requiring immediate drug discontinuation: 1

  • Raised red patches (hives)
  • Swelling of face, lips, tongue, or throat
  • Difficulty breathing or swallowing
  • Progressive or spreading rash

For isolated, mild rash without systemic symptoms, the reaction is likely benign and may not require discontinuation 2

Management Algorithm

Mild, Localized Rash

  • Continue dapagliflozin with close monitoring 3
  • Apply topical moisturizers or low-potency corticosteroids for symptomatic relief 3
  • Reassess within 1-2 weeks

Moderate Rash (spreading, pruritic, but no systemic symptoms)

  • Temporarily interrupt dapagliflozin therapy 3
  • Consider systemic antihistamines
  • If rash resolves completely, may attempt reintroduction at the same dose with careful monitoring 3

Severe Rash or Signs of Allergic Reaction

  • Stop dapagliflozin immediately and permanently 1
  • Do not rechallenge with the medication 1
  • Seek immediate medical evaluation, particularly if accompanied by blistering, mucosal involvement, or systemic symptoms 5
  • Consider systemic corticosteroids for significant reactions 3

Risk Factors for Skin Reactions

The following factors may increase the likelihood of dapagliflozin-associated skin reactions: 3

  • Higher doses of medication
  • Concomitant use of CYP3A4 inhibitors
  • Dehydration (particularly relevant given dapagliflozin's mechanism of action)

Special Consideration: Genital Rash

Rash of the penis is specifically mentioned as a symptom of yeast infection (balanitis), not allergic reaction. 1 This is a mechanism-related adverse effect occurring due to increased urinary glucose excretion and should be managed with antifungal therapy rather than drug discontinuation 1, 6, 7

Clinical Context

  • Genital mycotic infections are far more common than allergic rash, particularly in women, and represent the most frequent adverse event with dapagliflozin 6, 7, 8

  • Dapagliflozin does not lead to an increased risk of serious hypersensitivity reactions compared to other diabetes medications, including in Asian populations where initial concerns were raised 2

  • Long-term studies up to 4 years demonstrate that skin reactions remain infrequent and do not increase with prolonged exposure 7, 8

References

Guideline

Rosuvastatin-Associated Skin Rash

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Lisinopril‑Associated Cutaneous Reactions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Incidence of Skin Rash with Paracetamol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.